
[CLAIMS]

[Claim 1]

Use of a pharmaceutical composition comprising a compound of formula (I):

[Chem. 1]



(I)


wherein R^1, R^2, R^3, and R^4 are independently halogen or C_{1-3} alkyl,

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for preventing and/or treating a symptom and/or a disease related to enhanced induction of megakaryocyte differentiation.

[Claim 2]

The use of claim 1, wherein the compound of formula (I) is a compound of formula (Ia):

[Chem. 2]



(Ia)

[Claim 3]

The use of claim 1, wherein R^1 and R^2 are fluorine, and R^3 and R^4 are methyl.

[Claim 4]

The use of claim 1, wherein the compound of formula (I) is 6-(2,3-difluoro-4-(2-hydroxy-2-methylpropoxy)phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one or (R)-6-(2,3-difluoro-4-(2-hydroxy-2-methylpropoxy)phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one.

[Claim 5]

The use of any one of claims 1 to 4, wherein the symptom related to enhanced induction of megakaryocyte differentiation is increased platelet production.

[Claim 6]

The use of any one of claims 1 to 4, wherein the disease related to enhanced induction of megakaryocyte differentiation is essential thrombocythemia.